Zydus signs deal with CVS Caremark to include drugs in templates

Zydus Lifesciences today announced a landmark agreement with CVS Caremark, under which CVS Caremark will include Zydus’s diabetes medicines Zituvio, Zituvimet and Zituvimet XR in its template formulary beginning January 1, 2025. These medications are used to improve glycemic control in adults with type 2 diabetes and contain ingredients such as sitagliptin and metformin. After this announcement of the company, Zydus shares closed with a gain of 4.22 percent today.

These three NDAs for the sitagliptin (base) and combination franchise have been previously approved by the USFDA through the 505(b)(2) pathway. The Zituvio line of products includes the dipeptidyl peptidase-4 (DPP-4) inhibitor active ingredients sitagliptin and the biguanide metformin hydrochloride (HCI) that work as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Are.

Commenting on the move, Punit Patel, President and CEO, Zydus Pharmaceuticals USA Inc., said, “We are proud to partner with CVS Caremark, one of America’s most patient-centric healthcare solutions providers, with the aim of providing high To improve access to quality patients. Medicines.